The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Summary and future directions

Diabetes Care

Volumn 37, Issue 1, 2014, Pages 44-49

  Gubitosi Klug, Rose A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; COMPLICATION; DATA PROCESSING; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; DISEASE SURVEILLANCE; EVIDENCE BASED MEDICINE; FOLLOW UP; GENETICS; GLYCEMIC CONTROL; HEALTH ECONOMICS; HEALTH IMPACT ASSESSMENT; HEARING DISORDER; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KNOWLEDGE MANAGEMENT; LABORATORY DIAGNOSIS; LONGITUDINAL STUDY; MEDICAL EXAMINATION; MEDICAL HISTORY; MICROANGIOPATHY; NEUROPATHY; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PREVALENCE; PROTEIN SECRETION; QUESTIONNAIRE; RISK ASSESSMENT; SCREENING; VASCULAR DISEASE; ADOLESCENT; ADULT; AGED; BLOOD; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DOSE RESPONSE; FEMALE; GASTROINTESTINAL DISEASES; HEARING DISORDERS; MALE; MASS SCREENING; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECRETION (PROCESS); TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; TRENDS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; C-PEPTIDE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; HEARING DISORDERS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MASS SCREENING; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84892417939     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2148     Document Type: Article

References (42)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial.Arch Ophthalmol 1995;113:36-51
3. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial.Ophthalmology 1995;102:647-661
4. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-2167
5. Albers JW, HermanWH, Pop-Busui R, et al.;Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010;33:1090 1096
6. De Boer IH, Sun W, Cleary PA, et al.; DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365:2366-2376
7. Nathan DM, Zinman B, Cleary PA, et al.;Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years duration:the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983-2005).Arch Intern Med 2009;169:1307-1316
8. Jacobson AM, Braffett BH, Cleary PA, Gubitosi-Klug RA, Larkin ME; DCCT/EDIC Research Group. The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: A 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. Diabetes Care 2013;36:3131-3138
9. The DCCT Research Group. The Diabetes Control and Complications Trial (DCCT): Design and methodologic considerations for the feasibility phase. Diabetes 1986;35:530-545
10. Epidemiology of Diabetes Interventions and Complications (EDIC). Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term followup of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111
11. Turkbey EB, Backlund JY, Genuth S, et al.;DCCT/EDIC Research Group. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation 2011;124:1737-1746
12. The Diabetes Control and Complications Trial Research Group. Clustering of longterm complications in families with diabetes in the diabetes control and complications trial. Diabetes 1997;46:1829-1839
13. Cleary PA, Orchard TJ, Genuth S, et al.;DCCT/EDIC Research Group. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology ofDiabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006;55:3556-3565
14. Jenkins AJ, Lyons TJ, Zheng D, et al.; DCC/EDIC Research Group. Serumlipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications cohort: Associations with gender and glycemia. Diabetes Care 2003;26:810-818
15. Van Den Eeden SK, Sarma AV, Rutledge BN, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Research Group. Effect of intensive glycemic control and diabetes complications on lower urinary tract symptoms in men with type 1 diabetes: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes Care 2009;32: 664-670
16. Polak JF, Backlund JY, Cleary PA, et al.; DCCT/EDIC Research Group. Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes 2011;60:607 613
17. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 1999;48:383-390
18. Nathan DM, Lachin J, Cleary P, et al.; Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventionsand Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl JMed 2003;348:2294-2303
19. Genuth S, Sun W, Cleary P, et al.; DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes 2005;54:3103-3111
20. Jacobson AM, Paterson AD, Ryan CM, et al.;DCCT/EDIC Research Group. The associations of apolipoprotein E and angiotensin-converting enzyme polymorphisms and cognitive function in type 1 diabetes based on an 18-year followup of the DCCT cohort. Diabet Med 2010;27:15-22
21. Musen G, Jacobson AM, Ryan CM, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Impact of diabetes and its treatment on cognitive function among adolescents who participated in the Diabetes Control and Complications Trial. Diabetes Care 2008;31:1933-1938
22. Jacobson AM, Musen G, Ryan CM, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007;356:1842-1852
23. Pop-Busui R, Low PA, Waberski BH, et al.; DCCT/EDIC Research Group. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009;119: 2886-2893
24. Cleary PA, Braffett BH, Orchard T, et al.; DCCT/EDIC Research Group. Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Technol Ther 2013;15:466-474
25. Orchard TJ, Lyons TJ, Cleary PA, et al.; DCCT/EDIC Research Group. The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study. Diabetes Care 2013;36:3146-3153
26. Kramer JR, Bayless ML, Lorenzi GM, et al.; DCCT/EDIC Study Group. Participant characteristics and study features associated with high retention rates in a longitudinal investigation of type 1 diabetes mellitus. Clin Trials 2012;9:798-805
27. Nathan DM, McGee P, Steffes MW, Lachin JM; DCCT/EDIC Research Group.Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes 2014;63:282-290
28. Nathan DM, Steffes MW, Sun W, Rynders GP, Lachin JM. Determining stability of stored samples retrospectively: The validation of glycated albumin. Clin Chem 2011;57:286-290
29. Orchard TJ, Sun W, Cleary PA, et al.; DCCT/EDIC Research Group. Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes 2013;62:3218-3223
30. Al-Kateb H,Mirea L, Xie X, et al.; DCCT/EDIC Research Group. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: The DCCT/EDIC genetics study. Diabetes 2007;56: 2161-2168
31. Nathan DM; DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: Overview. Diabetes Care 2014;37:9-16
32. Aiello LP; DCCT/EDIC Research Group. Diabetic retinopathy and other ocular findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2014;37:17-23
33. De Boer IH; DCCT/EDIC Research Group. Kidney disease and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2014;37:24-30
34. Martin CL, Albers JW, Pop-Busui R; DCCT/EDIC Research Group. Neuropathy and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2014;37:31-38
35. Boright AP, Paterson AD, Mirea L, et al.; DCCT/EDIC Research Group. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: The DCCT/EDIC Genetics Study. Diabetes 2005;54:1238-1244
36. Al-Kateb H, Boright AP, Mirea L, et al.;Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics Study. Diabetes 2008;57:218-228
37. Hotaling JM, Waggott DR, Goldberg J, et al.; DCCT/EDIC Research Group. Pilot genomewide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort. J Urol 2012;188:514-520
38. Monnier VM, Bautista O, Kenny D, et al.; DCCT Skin Collagen Ancillary Study Group. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with longterm intensive versus conventional therapy of type 1 diabetes: Relevance of glycated collagen products versus HbA1c as markers of diabetic complications.Diabetes 1999; 48:870-880
39. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial:. a randomized, controlled trial. Ann Intern Med 1998;128:517-523
40. Axelsson A, Sigroth K, Vertes D. Hearing in diabetics. Acta Otolaryngol Suppl 1978;356:1-23
41. Bainbridge KE, Hoffman HJ, Cowie CC. Diabetes and hearing impairment in the United States: Audiometric evidence from the National Health and Nutrition Examination Survey, 1999 to 2004. Ann Intern Med 2008;149:1-10
42. Bharucha AE, Camilleri M, Veil E, Burton D,Zinsmeister AR. Comprehensive assessment of gastric emptying with a stable isotope breath test. Neurogastroenterol Motil 2013; 25:e60-e69 Kidney Diseases Kidney Diseases